Viltepso (viltolarsen) / Nippon Shinyaku, National Center of Neurology and Psychiatry  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Viltepso (viltolarsen) / Nippon Shinyaku, National Center of Neurology and Psychiatry
NCT04060199 / 2019-002076-13: Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

Completed
3
77
Europe, Canada, US, RoW
Viltolarsen, NS-065/NCNP-01, Placebo
NS Pharma, Inc., Nippon Shinyaku Co., Ltd.
Duchenne Muscular Dystrophy
10/23
10/23
NCT04768062 / 2021-000122-10: Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Active, not recruiting
3
74
Europe, Canada, Japan, RoW
Viltolarsen, NS-065/NCNP-01
NS Pharma, Inc., Nippon Shinyaku Co., Ltd.
Duchenne Muscular Dystrophy
10/25
11/25

Download Options